Functional Fibrinogen Activity (Clauss Method) is Superior for Assessing Bleeding Risk
For assessing bleeding risk, the Clauss fibrinogen assay is the preferred test because it measures functional clotting capacity rather than just protein quantity, which is what matters clinically when evaluating hemorrhagic risk. 1, 2, 3
Key Distinction Between the Two Tests
The fundamental difference lies in what each test measures:
- Clauss method (functional activity): Measures how much fibrinogen actually participates in clot formation by adding excess thrombin to diluted plasma and measuring clotting time 1
- Antigenic fibrinogen level (immunological test): Measures total fibrinogen protein concentration regardless of whether it functions properly 1
Why Functional Activity Matters More
Approximately 25% of circulating fibrinogen consists of degraded, low molecular weight forms (305 or 270 kDa) that are less effective in promoting clotting. 1 This means antigenic levels can appear normal while functional capacity is critically impaired—a dangerous scenario when assessing bleeding risk.
Critical Clinical Scenario: Dysfibrinogenemia
The most compelling evidence comes from dysfibrinogenemia studies where the distinction becomes life-threatening:
- In dysfibrinogenemia patients, PT-derived fibrinogen assays (which correlate with antigenic levels) overestimate functional fibrinogen by approximately 4-5 times compared to the Clauss assay 4, 3
- Median Clauss values in these patients: 0.40-0.60 g/L (critically low)
- Median antigenic/PT-derived values: 2.41-2.64 g/L (falsely reassuring) 3
- This discrepancy could erroneously report normal levels in patients at high bleeding risk, potentially delaying life-saving treatment 3
Guideline-Based Recommendations
International consensus guidelines consistently prioritize functional assessment:
- The 2019 European cardiac surgery guidelines specify using the Clauss method (reference range 1.8-3.5 g/L) as the standard laboratory test for fibrinogen measurement 1
- The 2023 European trauma guidelines recommend fibrinogen replacement based on functional fibrinogen deficiency using either Clauss < 1.5 g/L or viscoelastic evidence 5
- The 2024 ICSH recommendations state: "The Clauss fibrinogen assay remains the method of choice for the assessment of fibrinogen function" 2
Diagnostic Algorithm
When evaluating bleeding risk:
- Order Clauss fibrinogen as first-line test (reference range 1.8-3.5 g/L) 1
- If Clauss shows low fibrinogen but clinical picture doesn't match, add fibrinogen antigen testing to distinguish:
- In emergency settings, viscoelastic testing (ROTEM FIBTEM or TEG functional fibrinogen) provides functional assessment within minutes 1
Important Caveats
Reproducibility issues exist even among different Clauss assays:
- Photo-optical methods vs. mechanical methods can show substantial variation (6.4-8.5 g/L vs. 10.4-12.8 g/L for the same samples) 1
- Reproducibility is impaired in DIC, after thrombolytic therapy, and at very high fibrinogen levels 1
- Despite these limitations, Clauss still correlates better with actual bleeding risk than antigenic levels
Never rely on PT-derived fibrinogen alone for bleeding risk assessment—it correlates with antigen rather than function and can be dangerously misleading 3, 7. Recent 2026 data confirms Clauss has higher diagnostic accuracy than PT-derived methods for predicting low clot firmness (AUC 0.92 vs 0.90) 7.
Bottom Line for Clinical Practice
When a patient is bleeding or at risk of bleeding, you need to know how much functional fibrinogen is available to form clots, not just how much fibrinogen protein is floating around. The Clauss assay tells you this; antigenic levels do not. In dysfibrinogenemia, relying on antigenic levels could result in withholding critical fibrinogen replacement from a patient who desperately needs it 3.